Compound hub
Retatrutide
Retatrutide (LY3437943) is an experimental Eli Lilly peptide described in the published literature as acting on three receptor systems at once. This hub collects the questions people ask about it and answers each one from the trial record.
Record card
| Common name | retatrutide |
|---|---|
| Research code | LY3437943 |
| Developer | Eli Lilly |
| CAS | 2381089-83-2 |
| Discovery year | 2022 |
| Trial phase as of 2026 | Phase 3 |
| Approval as of 2026 | Approved in no country |
Questions answered here
04- Retatrutide vs Mounjaro vs Ozempic: what's the difference?Retatrutide, Mounjaro, and Ozempic compared by molecule, receptor systems, and approval status. Research material is not a medicine.Updated 2026-08-18
- How long has retatrutide been studied?Retatrutide's research record from the first dated human enrollment in December 2019 to Phase 3 in 2026. Research material is not a medicine.Updated 2026-08-19
- Retatrutide pharmacokinetics: what is the half-life?Retatrutide's published human pharmacokinetics: a half-life of about six days, and what has not been measured. Research material is not a medicine.Updated 2026-08-20
- Retatrutide Phase 2 trial: what did the paper find?A guided read of the retatrutide Phase 2 obesity trial (NEJM 2023): 338 adults, 48 weeks, and what the primary end point actually measured.Updated 2026-08-21
Form Laboratories supplies research-use-only reference material. Everything in this hub is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.